Ratio Therapeutics and PharmaLogic Expand Manufacturing Collaboration to Support Clinical Development of [Ac-225]RTX-2358
Summary
Ratio Therapeutics expanded its manufacturing collaboration with PharmaLogic to support clinical development of its lead radiotherapeutic candidate, [Ac-225]RTX-2358. The agreement increases manufacturing capacity by adding PharmaLogic's Idaho Falls facility and aims to improve redundancy and multi-dose batch production. The partnership is intended to support ongoing Phase 1/2 work and future later-stage and registrational trials in FAP-expressing tumors. Both companies frame the deal as a step toward scalable clinical supply and eventual commercial readiness.
Classifications
industries
No industries detected
applications
Accounting and Taxes
AskAI Classifications
Labels
Pharmaceutical Software
Radiopharmaceutical Technology
Medical Imaging Software
Linked Companies
PharmaLogic
up to $1M